Immunovant (NASDAQ:IMVT) Trading Down 6.8% – Time to Sell?

Immunovant, Inc. (NASDAQ:IMVT) fell 6.8% during mid-day trading on Wednesday . The stock traded as low as $35.34 and last traded at $34.7420. Approximately 701,117 shares traded hands during mid-day trading, a decline of 53% from the average daily volume of 1,500,243 shares. The stock had previously closed at $37.29.

Key Stories Impacting Immunovant

Here are the key news stories impacting Immunovant this week:

• Positive Sentiment: IMVT-1402 showed a favorable safety and tolerability profile consistent with prior studies. The company also said deeper IgG reductions were associated with improved clinical outcomes, while development timelines for its other programs remain on track. Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
• Neutral Sentiment: The study produced positive trends across multiple clinical measures, but those trends did not reach statistical significance on the primary endpoint: percentage change from baseline in CLASI-A score at Week 12. Immunovant said the treatment’s safety profile remained favorable. Immunovant Announces Topline Results from Period 1 of Proof-of-Concept Trial
• Negative Sentiment: Because the CLE study missed its primary goal and failed to meet Immunovant’s internal threshold for continuation, the company will stop developing IMVT-1402 in CLE. The loss of this development opportunity increases focus on the success of the remaining pipeline, contributing to shares moving toward a more than three-month low. Immunovant Pulls Plug on Lupus Program After Study Misses Primary Goal

Wall Street Analysts Forecast Growth

IMVT has been the subject of several research reports. Guggenheim raised their price objective on Immunovant from $44.00 to $62.00 and gave the stock a “buy” rating in a research note on Tuesday, May 26th. Sanford C. Bernstein raised Immunovant to a “hold” rating in a report on Wednesday, July 29th. JPMorgan Chase & Co. increased their price target on Immunovant from $47.00 to $50.00 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Immunovant in a research note on Tuesday, August 25th. Finally, Citigroup raised their target price on shares of Immunovant from $57.00 to $61.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Seven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Immunovant has an average rating of “Moderate Buy” and an average price target of $44.00.

Immunovant Stock Down 7.1%

The firm has a market capitalization of $7.16 billion, a PE ratio of -12.32 and a beta of 0.81. The business’s 50-day moving average price is $40.10 and its 200-day moving average price is $33.78.

Immunovant (NASDAQ:IMVT) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.12). The company had revenue of $7.09 million for the quarter, compared to analysts’ expectations of $7.09 million. During the same quarter in the previous year, the firm earned ($0.71) earnings per share. On average, analysts anticipate that Immunovant, Inc. will post -2.96 EPS for the current fiscal year.

Insiders Place Their Bets

In other Immunovant news, CTO Jay S. Stout sold 40,000 shares of the company’s stock in a transaction dated Friday, June 26th. The stock was sold at an average price of $38.31, for a total value of $1,532,400.00. Following the transaction, the chief technology officer directly owned 211,685 shares of the company’s stock, valued at $8,109,652.35. This represents a 15.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Eric Venker sold 3,092 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $38.48, for a total value of $118,980.16. Following the sale, the chief executive officer directly owned 254,280 shares of the company’s stock, valued at $9,784,694.40. This trade represents a 1.20% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 98,359 shares of company stock valued at $3,785,493 in the last three months. Company insiders own 1.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Engineers Gate Manager LP lifted its position in Immunovant by 179.7% during the 2nd quarter. Engineers Gate Manager LP now owns 24,220 shares of the company’s stock worth $933,000 after acquiring an additional 15,560 shares during the last quarter. Squarepoint Ops LLC acquired a new stake in Immunovant in the 2nd quarter valued at approximately $2,996,000. Nykredit A S bought a new position in Immunovant in the 2nd quarter worth approximately $174,000. Corient Private Wealth LP increased its position in Immunovant by 1.8% in the 2nd quarter. Corient Private Wealth LP now owns 24,522 shares of the company’s stock worth $945,000 after buying an additional 442 shares during the period. Finally, Amundi lifted its holdings in shares of Immunovant by 6.1% during the second quarter. Amundi now owns 70,948 shares of the company’s stock worth $2,734,000 after buying an additional 4,100 shares during the last quarter. Institutional investors and hedge funds own 47.08% of the company’s stock.

About Immunovant

Immunovant, Inc (NASDAQ: IMVT) is a clinical-stage biopharmaceutical company developing therapies for patients with immune-mediated diseases. The company focuses on conditions in which disease-causing antibodies, or immunoglobulin G (IgG), play a central role, including autoimmune and inflammatory disorders.

Immunovant’s lead product candidate is batoclimab, an investigational fully human monoclonal antibody designed to block the neonatal Fc receptor (FcRn). By inhibiting FcRn, batoclimab is intended to reduce circulating IgG antibodies that can contribute to autoimmune disease.